Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma

Cancer

Volumn 91, Issue 12, 2001, Pages 2246-2257

  Mayers, Catherine ^a   Panzarella, Tony ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvant cyclophosphamide; And 5 fluorouracil (CMF); Breast carcinoma; Clinical trial; Methotrexate; Myelosuppression

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035875895     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4     Document Type: Article

References (17)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Selection bias in clinical trials
3. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with non-participants in such trials
4. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland
5. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
6. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
7. Regression models and lifetables
8. Statistical aspects of prognostic factor studies in oncology
9. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
10. Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer
11. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
12. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
13. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil therapy in premenopausal women with node-positive breast cancer
14. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
15. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike?
16. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
17. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results